news
Evaluating the anti-obesity effects of tocotrienols
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
List view / Grid view
Parkinson's disease (PD)
article
Investigating antipsychotics in a Parkinson’s disease psychosis model
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
news
Truncated version of the SMN2 gene could revolutionise drug discovery
A condensed version of the SMN2 gene could improve discovery of potential therapies for spinal muscular atrophy and other conditions.
news
Mitigating oxidative stress in neurodegenerative diseases
Researchers have found that using protein-like polymers to inhibit the Keap1/Nrf2 PPI is a powerful therapeutic strategy.
news
Targeting GBA gene variants for treating Parkinson’s disease
A new project plans to elucidate the relationship between the glucosylceramidase beta gene and Parkinson’s disease.
news
Novel prediction tool accurately determines disease stage
A new learning-based framework enables patients and caregivers to predict the timing of any of the five clinical groups of AD development.
news
Neurodevelopmental defects seen in mini-brains with ANG mutation
Researchers found that ANG in its mutated form slows stem cell differentiation, resulting in neurodevelopmental defects in adult nerve cells.
news
Improved targeted ocular spectroscopy for better diagnosis
In vitro and in vivo experiments highlight the advantages of a new targeted spectroscopy system for many eye diseases.
news
Nano-sized traps enable better study of proteins
Researchers have developed a new method to study protein clumps that occur in many difficult-to-treat diseases.
news
Incorporating microglia into brain organoids
iPS-cell-derived microglia in brain organoids have enabled scientists to understand early brain development and microglia-associated disease.
article
New avenues for rare disease treatment
Drugs that boost autophagy hold great promise in preventing and halting neurodegenerative disorders. By ramping up the cell’s waste disposal system, they stimulate the removal of the toxic proteins that are a hallmark of brain conditions such as Alzheimer’s disease and Parkinson’s disease. Now, scientists are harnessing the power of…
news
New cell discovery shakes up neuroscience
Scientists have identified a novel cell type that combines astrocytic characteristics with the machinery for synaptic transmission. This discovery resolves years of debate in the field.
article
Brain macrophage in Parkinson’s disease neuroinflammation
A growing body of evidence pinpoints neuroinflammation as a pivotal factor driving brain-related pathogenesis. Yet, a crucial question lingers: among the various immune cell groups residing within the brain, which one orchestrates this inflammatory reaction?
article
Therapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
news
Three distinct brain circuits in the thalamus contribute to Parkinson’s symptoms
Targeting these brain circuits could offer a new way to reverse motor dysfunction and depression in Parkinson’s disease patients.